Sichuan Baili Pharmaceutical Co., Ltd.

This study is testing whether a new drug called BL-B01D1 works better than standard chemotherapy for people with advanced esophageal cancer that has returned or spread after their first treatment failed. It will involve about 497 adults whose cancer worsened despite prior immunot…

This study is testing whether a new drug called BL-B01D1 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. About 418 adults who have had 1-2 prior chemotherapy treatments will be rand…

This is an early-stage study to check the safety and find the right dose of a new drug called GNC-035. The drug is a special antibody designed to attack cancer cells in four different ways. It is being tested in adults with advanced blood cancers that have come back or have not r…

This study is testing whether adding an experimental drug called SI-B001 to standard chemotherapy can help control advanced non-small cell lung cancer that has worsened despite prior immunotherapy. It involves about 69 adults whose cancer has specific genetic markers (EGFR and AL…

This is an early-stage safety study testing a new experimental drug called SI-B003 in patients with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to block two different pathways (PD-1 and CTLA-4) that cancer cells use to hide from…

This early-stage study is testing a new, experimental drug called GNC-035 in adults with chronic lymphocytic leukemia and other blood cancers that have come back or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shows any sig…

This study is testing whether adding a new investigational drug called SI-B001 to an existing lung cancer medication (osimertinib) is safe and effective for people with advanced non-small cell lung cancer that has worsened after prior treatment. It aims to find the best dose of t…

This early-stage study is testing a new, experimental antibody drug called GNC-038 in adults whose diffuse large B-cell lymphoma (DLBCL) has come back or hasn't responded to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. Resea…

This early-stage trial is testing an experimental drug called BL-M02D1 in adults with advanced non-small cell lung cancer and other solid tumors that have stopped responding to standard treatments. The study first aims to find a safe and effective dose, then checks if the drug ca…

This is the first human study of an experimental antibody called GNC-035 for people with advanced breast cancer that has spread or returned after standard treatments. The main goal is to find a safe dose by testing it in 36 patients and watching for side effects. Researchers will…

This is a first-in-human study to test the safety and find the right dose of an experimental drug called BL-M02D1. It involves 22 adults with advanced gastrointestinal or other solid tumors that have spread and have no standard treatment options. The main goals are to see how muc…

This study is testing a new drug called BL-B01D1 against standard chemotherapy for people with advanced non-small cell lung cancer. It's for patients whose cancer has continued to grow despite treatment with EGFR-targeted drugs. The goal is to see if the new drug can better contr…

This study is testing a new drug combination for people with advanced head and neck cancer that has come back or spread after initial treatment. It aims to see if adding the experimental drug SI-B001 to the chemotherapy drug paclitaxel is safe and can help control the cancer. The…

This study is for people with advanced nasopharyngeal cancer (a type of throat cancer) that has returned or spread after they've already tried several other treatments, including immunotherapy and chemotherapy. It aims to see if a new drug called BL-B01D1 works better and is safe…

This study is testing a new drug called BL-B01D1, both by itself and combined with an existing lung cancer drug (osimertinib), for people with advanced non-small cell lung cancer. The main goals are to find the safest and most effective dose and to see how well the treatment shri…

This study is testing whether a new drug called SI-B001, when combined with an existing chemotherapy drug (irinotecan), can help control advanced esophageal cancer that has come back or spread after initial treatment. It involves 22 adults whose cancer worsened despite prior immu…

This early-stage study is testing an experimental drug called GNC-038 in adults with certain aggressive types of lymphoma that have returned or not responded to prior treatments. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors…

This is a very early-stage study to test the safety and side effects of a new drug called BL-B01D1 in adults with advanced cancers that have spread and have no standard treatment options. The main goals are to find the highest safe dose and see how the body processes the drug. It…

This early-stage study is testing a new, four-target antibody drug called GNC-038 in adults with primary or secondary brain lymphoma that has come back or hasn't responded to other treatments. The main goals are to find a safe dose, understand how the body processes the drug, and…

This is an early-stage study testing a new experimental drug called SI-B001 in people with advanced epithelial cancers that have spread and have no standard treatments left. The main goals are to find a safe dose and see how the body processes the drug. The study will enroll abou…

This study is testing an experimental drug called SI-B001 for people with advanced head and neck cancer that has come back or spread after standard treatments stopped working. It aims to see if the drug is safe and can help control the cancer. The trial is open to adults whose ca…

This is an early-stage study to test the safety and side effects of a new injectable drug called BL-M02D1 in adults with advanced triple-negative breast cancer or other solid tumors that have spread and have no standard treatment options. The main goals are to find the highest do…

This is an early-stage study testing the safety and dosing of a new experimental drug called GNC-038 in adults with aggressive blood cancers that have returned or not responded to standard treatments. The drug is a 'quad-specific antibody' designed to attack cancer cells by bindi…